NEWS
Meabco A/S has acquired the license to the BP-Cx-1 - carrier and
enhancer molecule GPL (Globular Polydentant Ligand).
BP-Cx-1 will be used in combination with other existing
chemotherapeutic agents as an enhancer, facilitating the efficacy
and reducing side effects.
Meabco’s new proprietary molecule may well open an entirely new
perspective in cancer treatment.
The ongoing comparative studies with agents from various cytostatic
groups show promising results.
